Key result
Catheter ablation for atrial tachycardia in adults with congenital heart disease was associated with fewer severe cardiovascular events than cardioversion (16.7% vs 48.6%; HR 0.46; 95% CI 0.22-0.93).
Why the study?
Atrial arrhythmias, particularly atrial tachycardia, are common complications in adults with congenital heart disease associated with high morbidity and mortality, prompting a comparison of mid-term outcomes according to arrhythmia management.
Does catheter ablation reduce severe cardiovascular events and arrhythmia recurrence compared to direct-current cardioversion in adults with congenital heart disease and atrial tachycardia?
Cohort (n=121)
Yes
Does catheter ablation reduce severe cardiovascular events and arrhythmia recurrence compared to direct-current cardioversion in adults with congenital heart disease and atrial tachycardia?
Catheter ablation for atrial tachycardia in adults with congenital heart disease is associated with a lower risk of arrhythmia recurrence and severe cardiovascular events compared to direct-current cardioversion.
May support ablation consideration in ACHD atrial tachycardia; leaves open need for randomized confirmation.
Atrial arrhythmias are common complications in adults with congenital heart disease (ACHD) and are associated with high morbi-mortality. Atrial tachycardia (AT) including intra-atrial reentrant tachycardia and focal atrial tachycardia are the most prevalent arrhythmias in ACHD. We aimed to compare mid-term outcomes according to arrhythmia management. All hospitalizations for AT in ACHD were retrospectively identified from medico-administrative database from September 2006 to September 2016 in two centers. Outcomes of patients with AT managed with direct-current cardioversion (DCCV) were compared with patients referred for catheter ablation (CA). Atrial arrhythmia recurrence, stroke, admission for heart failure and death were analyzed during follow-up. One hundred and twenty-one ACHD with AT (median age 41 [IQR 32–52] years, male 62%, 41% moderate CHD and 38% complex CHD) were included. Median follow-up was 3.3 years [IQR 1.4–6.2]. Thirty-seven (30.5%) patients underwent DCCV and 84 (69.5%) CA. No significant difference in age, CHD complexity, history of atrial arrhythmia, heart failure, and CHA2DS2-VASC score were observe. Patients undergoing DCCV had higher NYHA class. Atrial arrhythmia recurrence was lower in CA group (Log-rank test, p = 0.045). Most recurrences were AT, but atrial fibrillation was recorded in 35.1% after DCCV and 9.5% after CA (p = 0.001). At the end of follow-up, patients who were initially treated by CA had a significantly lower incidence of severe cardiovascular events (48.6% in DCCV group vs. 16.7% in CA group, HR: 0.46, CI 95%: 0.22–0.93, p = 0.031). A proactive management of AT by CA is associated with better long-term outcomes in ACHD.
No takes yet. Share an insight, caveat, or question.
Gallet et al. (2021) conducted a cohort in Atrial tachycardia in adults with congenital heart disease (n=121). Catheter ablation vs. Direct-current cardioversion was evaluated on Severe cardiovascular events (HR 0.46, 95% CI 0.22-0.93, p=0.031). Catheter ablation for atrial tachycardia in adults with congenital heart disease was associated with fewer severe cardiovascular events than cardioversion (16.7% vs 48.6%; HR 0.46; 95% CI 0.22-0.93).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: